Biotech Showcase™ program speakers have their fingers on the pulse of biotech

Biotech Showcase™ investor and partnering conference returns to San Francisco for the sixth year. This established innovation showcase for life science investors will be held January 13–15, 2014 at Parc 55 Wyndham San Francisco – Union Square. The event draws executives representing top public and private biotech and life science companies and investors seeking new opportunities.

Biotech Showcase, Streetwise Reports, and Sagient Research will present The Life Sciences Report Watchlist 2014 at the event again this year on Monday morning, including a welcome by Karen Roche, President of Streetwise Reports. The Watch List tracks major events in the industry from 2013 and makes predictions about trends for 2014. Mara Goldstein of Cantor Fitzgerald will moderate the session that includes panelists Michael G. King, Jr. of JMP Securities LLC; John McCamant of Medical Technology Stock Letter; Raghuram “Ram” Selvaraju of Aegis Capital; and George B. Zavoico of MLV &Co.

A closing reception and panel entitled “The Last Word” with The Life Sciences Report, RMI and BioPharm Insight will be held on Wednesday evening. This lively, and potentially irreverent, discussion will be moderated by Kimberly Ha of BioPharm Insight, and includes speakersFabrice Ergos of RMI Partners; Anthony Sun of Aisling Capital; and Desh Govender of Cedar Lane. Streetwise Reports is proudly providing Lookout Ridge Wines to support their Wine for Wheelchairs program. Lookout Ridge is dedicated to making exceptional wines and changing lives, one wheelchair at a time.

This year’s program features three lunch plenary topics with well-known industry thought leaders.

The Monday, January 13, lunch plenary, entitled “New models in biotechnology: Innovative structures, financing options and risk sharing opportunities,” will be moderated by Rich Riegerof Campbell Alliance and features panelists Martin J. Birkhofer of inVentiv Health Clinical;Bruce Booth of Atlas Venture; Paul Hastings of OncoMedGregory C. Simon of Poliwogg Holdings, Inc.; and Alex Zisson of Thomas McNerney.

“The return of optimism in the IPO market is good news, but we should always have multiple paths to maximize any one option, and we should continue to embrace innovative financing and partnering models as viable and lucrative alternatives,” said Hastings, who, besides his role as Chairman and CEO of OncoMed, is a well-known biotech industry advocate and chairman of the Biotechnology Industry Organization, emerging companies section.

Tuesday’s lunch plenary is moderated by Ellen B. Corenswet of Covington &Burling who will lead the discussion on “The Changing Dynamic of the Drug Development Ecosystem.” Panelists include Karen Bernstein of BioCenturyAnton Gopka of RMI Partners; Dan Mendelson of Avalere Health; and Dennis Purcell of Aisling Capital.

“Understanding the patient is the key to understanding the market,” said Gopka. “This is not new. What is new is the degree to which patients influence drug development areas based on need, based on accessibility, based on results. I think most biotech companies have realized that their connection to the patients can benefit their commercialization strategy. This panel should be an interesting discussion on who influences whom.”

The third lunch plenary will take place on Wednesday, and is entitled “How do you define value?” and will be moderated by Ben Bonifant of Triangle Insights Group. Panelists are Ron Cohen of Acorda Therapeutics, Inc.; Marc Dunoyer of AstraZenecaCraig Gordon of Capital Research; Evan McCulloch of Franklin Templeton Investments; and James Sabry of Genentech.

Other program highlights include business workshops on topics ranging from Parkinson’s disease, cancer checkpoints, molecular diagnostics, big data and FDA regulatory hurdles, and alternative financing.

Biotech Showcase is powered by partneringONE®, the industry’s most advanced partnering system that enables delegates to efficiently identify and arrange meetings with potential investors and partners.

View the program and register online.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
  • The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit

About Biotech Showcase™ 2014

Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

The 2013 edition showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. The 2013 event featured corporate presentations by 236 public and private biotechnology and life science companies, and drew 1,600 delegates who engaged in 2,500 one-to-one meetings.

Follow Biotech Showcase 2014 on Twitter: (hashtag: #BTS14)